Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2025-08-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for EyeGene Inc. (아이진 주식회사), covering the period from January 1, 2025, to June 30, 2025. It contains detailed company information, business descriptions, and management reports, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (4가 수막구균 접합백신 ‘EGMCV4의 국내 임상 제2/3상 임상시험계획 승인)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from a Korean company (EID) regarding the approval of a Phase 2/3 clinical trial by the Ministry of Food and Drug Safety (MFDS). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KIND system). Since it is a specific regulatory announcement regarding clinical trial status and does not fit into financial reporting or other categories, it is classified as a Regulatory Filing (RNS).
2025-06-30 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'EyeGene Inc.' (아이진 주식회사) covering the period from January 1, 2025, to March 31, 2025. It contains detailed financial data, business operations, and management information, which is characteristic of an interim/quarterly financial report. It is not a mere announcement or certification, as it provides substantive financial tables and business descriptions. Q1 2025
2025-05-15 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Supervisory Service/Korea Exchange. It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the exchange, and does not fit into the other more specific categories like DIRS (which is for personal trades) or SHA (which is for general share issuance).
2025-05-12 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (AGM). It details the approval of financial statements, the election of an auditor, and the approval of director/auditor compensation limits. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by the company '아이진' (Eyegene). It provides a summary of the audit opinion (which is 'unqualified' or '적정'), key financial data (assets, liabilities, equity, profit/loss), and confirms the receipt of the audit report from the external auditor (Samil PwC). While it contains financial data, it is a regulatory announcement of the audit results rather than the full 10-K annual report itself. According to the 'Menu vs Meal' rule, this is a notification of the filing of the audit report, which falls under the category of Report Publication Announcement (RPA). FY 2024
2025-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.